Literature DB >> 11391030

Activation of the endothelin system in insulin resistance.

R J Irving1, J P Noon, G C Watt, D J Webb, B R Walker.   

Abstract

Endothelin-1, released from the vascular endothelium after cleavage from big endothelin-1, is a potent paracrine vasoconstrictor peptide. Small studies suggest that circulating levels of endothelin-1 are elevated in subjects with cardiovascular risk factors. Big endothelin-1 levels may better reflect endothelin-1 generation. We examined relationships between plasma endothelin-1, plasma big endothelin-1, and predisposition to hypertension or other cardiovascular risk factors associated with insulin resistance in a large group of healthy young men. We recruited 96 healthy men aged 24-33 years from a cohort of 864 young men and women in whom predisposition to hypertension had been defined on the basis of their own blood pressure and the blood pressures of their parents. They attended after an overnight fast for measurement of blood pressure, anthropometry, and plasma lipids, insulin, glucose, endothelin-1 and big endothelin-1. Plasma endothelin-1 and big endothelin-1 levels did not correlate with blood pressure (r=0.09, -0.002 respectively) and were not influenced by parental blood pressure. Higher plasma endothelin-1 levels were associated with higher body mass index (r=0.29, p<0.005), and higher plasma insulin (r=0.21, p<0.05). Higher plasma big endothelin-1 levels were associated with insulin resistance, as assessed by the Homeostasis Model of Assessment resistance index (r=0.30, p<0.005). Endothelin-1 levels are not related to blood pressure, but are higher in healthy young men with insulin resistance and obesity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391030     DOI: 10.1093/qjmed/94.6.321

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  6 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

2.  Endothelin-1 impairs glucose transporter trafficking via a membrane-based mechanism.

Authors:  Andrew B Strawbridge; Jeffrey S Elmendorf
Journal:  J Cell Biochem       Date:  2006-03-01       Impact factor: 4.429

3.  Investigating the association between K198N coding polymorphism in EDN1 and hypertension, lipoprotein levels, the metabolic syndrome and cardiovascular disease.

Authors:  Steven Wiltshire; Brenda L Powell; Michelle Jennens; Pamela A McCaskie; Kim W Carter; Lyle J Palmer; Peter L Thompson; Brendan M McQuillan; Joseph Hung; John P Beilby
Journal:  Hum Genet       Date:  2008-02-21       Impact factor: 4.132

Review 4.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

5.  Associations of EDNRA and EDN1 polymorphisms with carotid intima media thickness through interactions with gender, regular exercise, and obesity in subjects in Taiwan: Taichung Community Health Study (TCHS).

Authors:  Tsai-Chung Li; Chia-Ing Li; Li-Na Liao; Chiu-Shong Liu; Chuan-Wei Yang; Chih-Hsueh Lin; Jen-Hao Hsiao; Chih-Yi Hsiao; Wen-Yuan Lin; Fang-Yang Wu; Cheng-Chieh Lin
Journal:  Biomedicine (Taipei)       Date:  2015-05-29

6.  Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1.

Authors:  Silvia Gogg; Ulf Smith; Per-Anders Jansson
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.